The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment
Regulatory T cells (Tregs) are essential for maintaining immune homeostasis and preventing autoimmune diseases, but are also a major cellular constituent of the tumor microenvironment (TME) that facilitates cancer progression. Identifying differences in Treg subtypes to specifically disrupt the activities of tumor-promoting Tregs, without affecting Tregs that maintain immune homeostasis remain a challenge. Here, we report that expression of the chromatin-organizer protein special AT-rich sequence binding protein 1 (Satb1), in Tregs is critical for their tumor-promoting functions in the TME, but not strictly required to suppress inflammatory T cells in autoimmune colitis. Satb1 expression differentiated between two Treg subtypes with distinct display of Treg phenotypic markers in lymphoid organs. Using transfer experiments, we discovered a context-specific switch in Satb1 protein expression between the two Treg subtypes. In mice, Treg-specific deletion of Satb1 augmented TCF-1 expression via a signaling axis involving Stat3 and the RNA-binding protein poly(C)-binding protein 1 (PCBP1), impairing the activities of tumor-infiltrating Treg cells. Simultaneous deletion of Satb1 and PCBP1 in Tregs completely restored Treg pro-tumorigenic functions and abolished the potent antitumor immune responses observed in Satb1-deficient mice. Our results reveal a key mechanism that may safely and potently enhance antitumor immunity without causing systemic autoimmune diseases. Identifying differences in Treg subtypes to disrupt the activities of tumor-promoting Tregs remains a challenge. Here, the authors report that Treg expression of SATB1 distinguishes pro-tumorigenic Tregs from Tregs that maintain immune homeostasis.
Authors
- Partha Biswas (ORCID: https://orcid.org/0000-0002-9766-756X)
- Zihai Li (ORCID: https://orcid.org/0000-0003-4603-927X)
- Ephraim Abrokwa Ansa-Addo (ORCID: https://orcid.org/0000-0002-9352-1109)
- Mark P. Rubinstein (ORCID: https://orcid.org/0000-0003-4748-0286)
- Huai‐Cheng Huang (ORCID: https://orcid.org/0000-0002-2650-3736)
- Payton Weltge (ORCID: https://orcid.org/0000-0001-9404-6744)
- Maria Velegraki (ORCID: https://orcid.org/0000-0003-3062-9777)
- Scott I. Abrams (ORCID: https://orcid.org/0000-0002-8742-4708)
- Eugene M. Oltz (ORCID: https://orcid.org/0000-0002-2513-7156)
- Parviz Azimnasab-sorkhabi (ORCID: https://orcid.org/0000-0003-0601-1328)
- Dongjun Chung (ORCID: https://orcid.org/0000-0002-8072-5671)
- Musab Bouhajra (ORCID: https://orcid.org/0000-0003-1010-0665)
- Mohammadreza Sepand
- Donna Bucci
- Afryea Henderson
- Brian P. Riesenberg
Institutions
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- National Taiwan University (TW)
- Wright State University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- National Taiwan University Hospital (TW)
- UNC Lineberger Comprehensive Cancer Center
- The Ohio State University (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-10-07
- DOI
- https://doi.org/10.1038/s41467-026-78360-9
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.00